{"id":1382,"date":"2020-09-30T23:00:00","date_gmt":"2020-09-30T23:00:00","guid":{"rendered":""},"modified":"2020-09-30T23:00:00","modified_gmt":"2020-09-30T23:00:00","slug":"tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week-randomized-double-blind-multicentre-placebo-controlled-phase-iii-trials-ecztra-1-and-ecztra-2","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/09\/30\/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week-randomized-double-blind-multicentre-placebo-controlled-phase-iii-trials-ecztra-1-and-ecztra-2\/","title":{"rendered":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two\u00a052-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)."},"content":{"rendered":"<p>Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early [&#8230;]\n","protected":false},"excerpt":{"rendered":"<p>Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early &#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[86],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1382"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=1382"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1382\/revisions"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=1382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=1382"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=1382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}